A carregar...

The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile

Reboxetine is the first commercially available norepinephrine reuptake inhibitor developed specifically as a first line therapy for major depressive disorder. In vitro and in vivo pharmacological studies indicated that reboxetine methanesulphonate has high affinity and selectivity for the human nore...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CNS Drug Rev
Main Authors: Hajós, Mihály, Fleishaker, Joseph C., Filipiak‐Reisner, Jacqueline K., Brown, Mark T., Wong, Erik H. F.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2006
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6741733/
https://ncbi.nlm.nih.gov/pubmed/14978512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1527-3458.2004.tb00002.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!